Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Winner

Neurology with Special Qualifications in Child Neurology West Palm Beach, FL Doctor of Osteopathy

NPI 1831201243 CMS profile 1268856

4631 N Congress Ave, Suite 200, West Palm Beach, FL 33407

Open in the dashboard

General payments

$624,223

1,211 records reported · program years 2019–2025

Research payments

$75,523

Paid to them · 24 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$17,771,840 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Paul Winner of West Palm Beach, FL is reported in the CMS Open Payments database as having received $624,223 across 1,211 general payments and $75,523 in research payments paid to them. Separately, studies naming them as principal investigator received $17,771,840 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,215 112
2024 General $18,569 127
2024 Research $49,836 9
2023 General $27,361 153
2023 Research $19,780 7
2022 General $65,318 157
2022 Research $805 2
2021 General $137,250 215
2021 Research $995 2
2020 General $196,439 215
2020 Research $511 3
2019 General $163,071 232
2019 Research $3,596 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Winner
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Paul Winner were reported at $16,215. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Paul Winner Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $163,071 $262 $68–$1,313 $163
2020 $196,439 $188 $46–$1,222 $114
2021 $137,250 $183 $45–$1,356 $132
2022 $65,318 $229 $72–$1,177 $149
2023 $27,361 $269 $93–$1,195 $160
2024 $18,569 $300 $98–$1,428 $164
2025 $16,215 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $183,899 205 payments
  2. Teva Pharmaceuticals USA, Inc. $151,317 121 payments
  3. Amgen Inc. $96,463 96 payments
  4. Lundbeck LLC $46,246 73 payments
  5. Allergan Inc. $41,348 51 payments
  6. AbbVie, Inc. $34,127 134 payments
  7. Axsome Therapeutics, Inc. $11,919 8 payments
  8. H. Lundbeck A S $9,837 6 payments
  9. Biohaven Pharmaceuticals, Inc. $9,796 13 payments
  10. Novartis Pharmaceuticals Corporation $9,436 70 payments
  11. Other $29,835 434 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $419,010 260 payments
  2. Consulting Fee $91,615 32 payments
  3. Honoraria $52,551 20 payments
  4. Travel and Lodging $36,064 81 payments
  5. Food and Beverage $24,753 811 payments
  6. Education $144 5 payments
  7. Grant $85 2 payments
Products named General payments · program years 2019–2025
  1. AJOVY Central Nervous System $131,772 88 payments
  2. EMGALITY $99,800 99 payments
  3. AIMOVIG $96,493 100 payments
  4. REYVOW $79,379 86 payments
  5. UBRELVY Neuroscience $32,367 46 payments
  6. UBRELVY Neuroscience $30,794 77 payments
  7. VYEPTI $30,673 41 payments
  8. Ajovy Central Nervous System $19,383 28 payments
  9. QULIPTA $14,125 84 payments
  10. Symbravo $11,919 8 payments
  11. Other $55,288 597 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $54,658 9 payments
  2. Pfizer Inc. $19,370 6 payments
  3. Sanofi US Services Inc. $820 8 payments
  4. Novartis Pharmaceuticals Corporation $675 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

531

Median for Neurology: 833

Drug cost

$133,926

Median for Neurology: $202,670

Branded share of claims

27.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aimovig Autoinjector Erenumab-Aooe Brand 48 $48,355
Qulipta Atogepant Brand 20 $22,034
Botox Onabotulinumtoxina Brand 13 $16,305
Nurtec Odt Rimegepant Sulfate Brand 11 $14,869
Ubrelvy Ubrogepant Brand 12 $12,019
Emgality Pen Galcanezumab-Gnlm Brand 13 $8,954
Savella Milnacipran Hcl Brand 11 $2,653
Verapamil Sr Verapamil Hcl Brand 18 $1,853
Sumatriptan Succinate Generic 38 $1,715
Pregabalin Generic 37 $1,042

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$72,456

Medicare's payments for the services billed

Medicare patients

121

Average age 76

Services billed

4,670

74 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Alzheimer's or dementia 43%
Ischemic heart disease 40%
Depression 36%
Chronic kidney disease 28%
Osteoporosis 27%
Diabetes 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AJOVY
$4,015 — —
UBRELVY
$3,389 12 —
QULIPTA
$3,340 20 —
Apokyn
$742 — —
Leqembi
$387 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

1,235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record